Physician profile
Jason E Kaplan
NPI 1184966277
$4,899.05
in general payments reported to CMS, 2019-2025
32 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,292 · 2020: $89.02 · 2022: $381 · 2023: $105 · 2024: $1,628 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $894.80 | 2019-2025 | Xience Skypoint, Coroflow, Esprit |
| Shockwave Medical, INC | $673.65 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $410.74 | 2019-2025 | Orsiro Mission, Pantera Leo |
| Edwards Lifesciences Corporation | $327.56 | 2022-2025 | Sapien 3 Ultra Resilia |
| Cordis US Corp. | $267.44 | 2024-2025 | Mynx Control Venous, Mynx Venous Vcd, Mynx Control |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $265.94 | 2019-2024 | Lifevest |
| Medtronic, INC. | $210.59 | 2024-2025 | Symplicity G3, Abre, Hawkone |
| Inari Medical, INC. | $208.17 | 2022 | |
| Heartflow, INC. | $172.97 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $167.92 | 2019-2024 | Camzyos |
| Pfizer INC. | $125.20 | 2019 | |
| Novo Nordisk INC | $124.74 | 2025 | Wegovy |
| Terumo Medical Corporation | $121.79 | 2025 | Metacross Otw, Angio-Seal, Glidewire |
| Teleflex LLC | $116.30 | 2024 | Turnpike, Trapliner |
| Angiodynamics, INC. | $115.64 | 2024-2025 | Alphavac, Angiovac |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $112.68 | 2024 | Indigo System |
| Cardiva Medical, INC. | $77.44 | 2024 | Cardiva Vascade 5f Vcs |
| Cagent Vascular INC | $73.41 | 2024 | Serrantor |
| Sanofi-Aventis U.S. LLC | $71.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $54.04 | 2019-2024 | Andexxa |
| Novartis Pharmaceuticals Corporation | $49.70 | 2019-2020 | |
| Amgen INC. | $45.49 | 2019 | |
| Imperative Care, INC | $37.96 | 2025 | Prodigy Catheter |
| Boston Scientific Corporation | $29.11 | 2019 | |
| Philips North America LLC | $27.43 | 2025 | Coronary Other |
| Alnylam Pharmaceuticals INC. | $26.99 | 2022 | |
| Glaxosmithkline, LLC. | $17.52 | 2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $14.97 | 2019 | |
| Janssen Biotech, INC. | $14.92 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.44 | 2019 | |
| Amarin Pharma, INC. | $13.88 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.